Top Ten most popular articles on Pharmafile.com this week
Stories have erupted out of the industry this week with leaps forward in malaria and cancer R&D, some controversial drug acceptances and rejections on both sides of the Atlantic, and even an app which has been officially deemed as effective as the pill.
Also, don't miss our recent features deconstructing Pfizer's record fine for overcharging the NHS and how this came to be, as well as our rundown of the top five European countries by pharmaceutical spending per capita.
Sir Alasdair Breckenridge has warned that Britain’s exit from the EU could lead to delays in key cancer treatments reaching patients if it also chooses to divorce itself from the EMA.
Novartis has agreed a collaboration deal with Cerulean Pharma to develop and market potential nanoparticle-drug conjugates, with the deal being worth $1.2 billion depending on milestonse.
The US Food and Drug Administration (FDA) has announced that it has approved Valeant Pharmaceutical’s injectable psoriasis treatment Siliq (brodalumab) for use in the United States, despite earlier concerns over risks it could pose to patients.
A new era of vaccine development could be heralded by the 100% protection offered by a vaccine developed to fight malaria.
New dual action drug ALM201 could be used to treat cancer patients in whom all other treatment avenues have failed.
MSD, Alzheimer's sufferers and their supporters, were hit another blow as yet another treatment failed at Phase 2/3 stage. The drug, verubecestat, failed to show that it was having any improvement upon patients and the drug was therefore discontinued.
Last year, Pfizer was fined a record sum for overcharging the NHS by exploiting regulation to hike the price of its drug Epanutin by 2,600%. Dr Farasat Bokhari and Professor Bruce Lyons dissect the incident to understand exactly how it came to be.
AstraZeneca’s Daxas (roflumilast) has been knocked back in draft guidance by the NICE, rejected by the regulator as a treatment for chronic obstructive pulmonary disease (COPD).
Fertility app Natural Cycles has become the first-ever smartphone application and software solution to be approved by experts as a viable alternative to conventional contraceptive methods.
We arranged the top five European countries by the levels of expenditure upon pharmaceuticals; not all are from the largest countries and there's a surprise omission.